MIAMI, Nov. 13, 2025 (GLOBE NEWSWIRE) — Inter&Co Inc. (NASDAQ: INTR | B3: INBR32), the leading super app providing financial and digital commerce services to over 41 million customers, today reported its results for the third quarter of 2025. 3Q25 Highlights: Inter printed another quarter of outstanding growth across all key metrics, while maintaining its disciplined approach to sustainable profitability.Client Growth: Added a record 1.2 million new active clients in the quarter, bringing the total active client base to 24 million, a testament to the platform’s compelling value proposition. Net Income: Reached R$336 million (US$63.2 million1), representing 39% year-over-year growth, successfully balancing investments in growth with operational efficiency. Credit Expansion: The credit portfolio expanded 30% YoY, triple...

Company plans to initiate Phase 1 clinical study of semaglutide implant for chronic weight management in the first half of 2026 and parallel investments in studies to enable rapid initiation of Phase 2 dose-ranging study, pending Phase 1 results and regulatory feedback 3Q 2025 private placement, together with October financings, generated approximately $25.7M in cash and cash commitments to support accelerated development of NPM-139 while securing financial position into 2027 ALAMEDA, Calif., Nov. 13, 2025 (GLOBE NEWSWIRE) — Vivani Medical, Inc. (Nasdaq: VANI) (“Vivani” or the “Company”), a biopharmaceutical company developing miniaturized, ultra long-acting drug implants, today reported financial results for the third quarter ended September 30, 2025, and provided a business update. Vivani Chief Executive Officer Adam Mendelsohn,...

Third quarter 2025 GAAP net income of $4.05 million or $0.30 per basic weighted average common share and Distributable Earnings(1) of $4.12 million or $0.31 per basic weighted average common share WEST PALM BEACH, Fla., Nov. 13, 2025 (GLOBE NEWSWIRE) — Sunrise Realty Trust, Inc. (Nasdaq: SUNS) (“SUNS” or the “Company”), a lender on the Tannenbaum Capital Group (“TCG”) Real Estate platform, today announced its results for the quarter ended September 30, 2025. SUNS reported generally accepted accounting principles (“GAAP”) net income of $4.05 million or $0.30 per basic weighted average common share and Distributable Earnings of $4.12 million or $0.31 per basic weighted average common share for the third quarter of 2025. Brian Sedrish, Chief Executive Officer of SUNS, said, “Our accomplishments during the third quarter demonstrate...

Announced iPSC derived beta islet cell program for Type 1 diabetes (T1D); Investigational New Drug (IND)-enabling studies expected to initiate by year-end 2025; IND submission planned in 2026 CNTY-308 advancing through IND-enabling studies to support planned clinical study initiation in 2026 Estimated cash runway into 4Q 2027PHILADELPHIA, Nov. 13, 2025 (GLOBE NEWSWIRE) — Century Therapeutics, Inc. (‘Century’, NASDAQ: IPSC), a biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies for autoimmune diseases and cancer, today reported financial results for the third quarter ended September 30, 2025, and provided a business update. “Today we announced our iPSC derived beta islet program for T1D. We have generated a compelling preclinical data package that underscores the tremendous opportunity...

Company Announced Completion of VERSATILE-002 Phase 2 trial of PDS0101 + Pembrolizumab in HPV16-Positive Recurrent/Metastatic Head and Neck Cancer Phase 2 Results Lead Company to Seek Expedited Approval Pathway in OngoingVERSATILE-003 Phase 3 Trial Design Conference Call and Webcast today at 8:00 a.m. Eastern Time PRINCETON, N.J., Nov. 13, 2025 (GLOBE NEWSWIRE) — PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers, today provided a business update, reported financial results for the third quarter ended September 30, 2025, and provided a clinical programs update. “Our request to meet with the FDA to propose an amendment to our ongoing VERSATILE-003 Phase 3 trial represents the culmination of the...

MONTREAL, Nov. 13, 2025 (GLOBE NEWSWIRE) — Dynacor Group Inc. (TSX: DNG) (“Dynacor” or the “Corporation”) today announced its unaudited financial and operational results1 for the third quarter ended September 30, 2025. “This was a solid third quarter that reflects our team’s resolve to deliver strong operational results that are more representative of the usual Dynacor performance,” said Jean Martineau, President & CEO. “Despite ore supply disruptions in the first two weeks in the quarter, we are well on track to meet or beat our full-year production and financial guidance. The higher gold prices and consistent mill performance generated a number of new financial records including record quarterly EBITDA. With our strong cash flow generation and strengthened management team, we continue to cultivate shareholder value through...

Strong financial position with cash, cash equivalents and marketable securities of $93.7M   Moderna litigation U.S. trial scheduled for March 2026;Favorable claim construction ruling in Pfizer-BioNTech litigation issued in September 2025   Additional analysis of imdusiran (AB-729) clinical data shows:– 46% of Phase 2a patients met criteria to discontinue all treatment– 94% of long-term follow-up patients remain off all treatment for up to 2+ years– 100% of HBV DNA positive patients in Phase 1b achieved HBV DNA levels belowquantification after only 18 weeks of imdusiran and nucleos(t)ide analogue therapy– All HBV e-antigen positive patients demonstrated dose-dependent HBV e-antigen decreases   WARMINSTER, Pa., Nov. 13, 2025 (GLOBE NEWSWIRE) — Arbutus Biopharma Corporation...

OMAHA, NE, Nov. 13, 2025 (GLOBE NEWSWIRE) — FitLife Brands, Inc. (“FitLife” or the “Company”) (NASDAQ: FTLF), a provider of innovative and proprietary nutritional supplements and wellness products, today announced financial results for the third quarter ended September 30, 2025. Highlights for the third quarter ended September 30, 2025 include:On August 8, 2025, the Company completed the acquisition of substantially all of the assets of Irwin Naturals (“Irwin”), and Irwin’s operating results for the period of August 9 through September 30 are included in FitLife’s consolidated financials for the third quarter of 2025. Total revenue was $23.5 million, an increase of 47% compared to the third quarter of 2024.   Wholesale revenue was $13.2 million, representing 56% of revenue and an increase of 156% compared to the third quarter...

Phase 1 clinical trial to evaluate the PK of a combination of denifanstat and resmetirom ongoing with data readout expected 1H 2026 First-in-human Phase 1 clinical trial of FASN inhibitor TVB-3567 ongoing Ascletis announced completion of its pre-NDA consultation with China’s NMPA and plans to submit an NDA for denifanstat in China for treatment of moderate-to-severe acne vulgaris SAN MATEO, Calif., Nov. 13, 2025 (GLOBE NEWSWIRE) — Sagimet Biosciences Inc. (Sagimet, Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today reported financial results for the quarter ended September 30, 2025, and provided recent corporate updates. “This is a dynamic period for Sagimet as we explore the therapeutic potential of FASN inhibition across different...

Reported late-breaking Phase 2 data at SITC for vilastobart demonstrating a 40% ORR in heavily pretreated patients with MSS mCRC without liver metastases and high plasma tumor mutational burden  Presented Phase 1 data at SITC for efarindodekin alfa showing promising monotherapy anti-tumor activity and generally well-tolerated safety profile in patients with advanced solid tumors Announced new preclinical data at SITC for masked T cell engager programs supporting best-in-class potential and showing efficient masking, potent anti-tumor activity and broad therapeutic index Anticipate cash runway into the first quarter of 2027 WALTHAM, Mass., Nov. 13, 2025 (GLOBE NEWSWIRE) — Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people...